MedGenome, a genomics-driven diagnostics company, has announced the launch of MetaSeq, an advanced blood test aimed at strengthening its infectious disease diagnostics portfolio and enabling faster, more comprehensive detection of bloodstream infections (BSIs).

MetaSeq uses metagenomic next-generation sequencing (NGS) to analyse microbial cell-free DNA (cfDNA) present in the bloodstream. The test can identify over 1,400 clinically relevant pathogens in a single assay, including bacteria, fungi, parasites, and DNA viruses, without requiring multiple targeted diagnostic tests.

Bloodstream infections are traditionally diagnosed through blood culture methods that can take several days and may produce negative results in patients already receiving antibiotics. By detecting microbial DNA directly from blood samples, MetaSeq enables infection identification even when conventional diagnostics are inconclusive. The test delivers results in approximately five days and has demonstrated higher sensitivity compared to standard blood culture, supporting earlier clinical decision-making, particularly for critically ill and immunocompromised patients.

MetaSeq is CE-IVD validated for peripheral blood samples and can also be performed on other clinical sample types such as cerebrospinal fluid, synovial fluid, and ascitic fluid.

Vedam Ramprasad, PhD, CEO, MedGenome Labs Ltd, said that diagnosing bloodstream infections remains complex, often requiring symptom-based provisional diagnosis and probability-driven treatment decisions. He noted that MetaSeq is designed to enable earlier and more accurate diagnosis, providing molecular-level insights to support targeted disease management and improve clinical decision-making.

The test has been developed in partnership with Germany-based pathogen diagnostics company Noscendo and is powered by Noscendo’s DISQVER® platform, which uses bioinformatics algorithms for pathogen identification. DISQVER® is recognised by the World Health Organization as a clinically approved NGS platform for diagnosing invasive fungal diseases.

Andreas Käpplein, CEO, Noscendo, said the collaboration aims to advance infection diagnostics in South Asia by enabling more precise and faster pathogen identification, supporting improved treatment outcomes in critical cases.

With the launch of MetaSeq, MedGenome continues to expand its genomics-based diagnostics offerings, focusing on improving infectious disease detection and supporting more precise management of serious infections.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!